Corona research: Consortium of Berlin research and industry seeks active ingredients
Protein crystals are analysed in the MX laboratory at BESSY II with hard X-rays. © C. Feiler/HZB
At BESSY II, Prof. Rolf Hilgenfeld (Uni Lübeck) was able to analyse an important protein of the SARS-CoV2 virus, the viral main protease which enables the virus to multiply. © H.Tabermann/HZB
The Berlin biotech company Molox GmbH and a team at the Helmholtz-Zentrum Berlin (HZB) have initiated a consortium of regional research groups and BASF. Together, they want to identify a starting point for the development of a potential active substance against the new coronavirus. Targets of potential inhibitors will be SARS-CoV2 proteins that promote the spread or infectivity of the viruses. Scientists from Freie Universität Berlin are also involved in the research work.
"Berlin combines important large-scale infrastructure with an excellent network of academic and industrial structural biologists and biochemists. The distances here are short, but resources and expertise must be strategically coordinated to be successful," says Dr. Holger von Moeller, the owner of the biotech company Molox.
Access to synchrotron radiation is essential for the success of the project. This particularly intense radiation is provided by the Berlin Electron Storage Ring for Synchrotron Radiation (BESSY II), which is operated by the HZB.
Several research groups at Freie Universität Berlin led by Prof. Markus Wahl, Prof. Christian Freund, Dr. Ursula Neu, and Prof. Sutapa Chakrabarti are working with Molox to produce the proteins and then crystallize them.
"The HZB is making all existing infrastructures available to the joint project," explains Dr. Manfred Weiss, head of the Research Group Macromolecular Crystallography (MX) at HZB.
BASF is the first project partner from the chemical industry to provide funds to start the investigations. Protein crystals will be saturated with potential inhibitors and subsequently analysed on the MX beamlines of BESSY II. In this way it can be discovered which compounds are particularly good at inhibiting the function of the protein - these should then be the starting points for the development of active substances.
The consortium is currently negotiating with other partners in order to acquire them and their substance libraries. "We are looking forward to this joint project and hope that we will be able to identify new potential active substances against SARS-CoV-2 very quickly", says Dr. Christian Feiler, project leader at HZB.
- Ernst Eckhard Koch Prize and Synchrotron Radiation Innovation AwardThis year, the Friends of Helmholtz-Zentrum Berlin (Freundeskreis des HZB e. V.) awarded the Ernst Eckhard Koch Prize to Dr. Dieter Skroblin of the Technische Universität Berlin for his outstanding doctoral thesis. The European Innovation Award Synchrotron Radiation went to Dr. Manfred Faubel from the Max Planck Institute for Dynamics and Self-Organization in Göttingen and Dr. Bernd Winter from the Fritz Haber Institute in Berlin. The award ceremony took place at this year's HZB user meeting.
- Modernisation of BESSY II+ light sourceThe focus of the User Meeting 2024: Helmholtz-Zentrum Berlin (HZB) presents the BESSY II+ upgrade programme. It enables world-class research at BESSY II to be further expanded and new concepts to be tested with regard to the successor source BESSY III.
- Less is more: Why an economical Iridium catalyst works so wellIridium-based catalysts are needed to produce hydrogen using water electrolysis. Now, a team at HZB has shown that the newly developed P2X catalyst, which requires only a quarter of the Iridium, is as efficient and stable over time as the best commercial catalyst. Measurements at BESSY II have now revealed how the special chemical environment in the P2X catalyst during electrolysis promotes the oxygen evolution reaction during water splitting.